Compare KTTA & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTTA | IDAI |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 15.9M |
| IPO Year | 2021 | 2022 |
| Metric | KTTA | IDAI |
|---|---|---|
| Price | $0.38 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 282.6K | 44.2K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | 76.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $486,559.00 | N/A |
| Revenue This Year | N/A | $59.48 |
| Revenue Next Year | N/A | $199.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3130.37 | N/A |
| 52 Week Low | $0.28 | $1.17 |
| 52 Week High | $2.06 | $5.28 |
| Indicator | KTTA | IDAI |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 48.14 |
| Support Level | $0.36 | $2.79 |
| Resistance Level | $0.52 | $3.53 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 14.56 | 64.94 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.